Law.com Subscribers SAVE 30%
Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
When Med Mal and Mass Tort Claims Overlap
Medical malpractice litigation is often complex, in-depth, and issue-heavy. Mass tort litigation is also often complex, in-depth, and issue-heavy. What happens when those two areas of practice converge during the course of a case? The answer to that question depends, of course, on the facts of each specific case. However, the issues that face attorneys on all sides of the litigation cannot be ignored.
Mass tort claims are typically claims made by individual plaintiffs against a manufacturer of a pharmaceutical or medical device. Prescription drugs require a treating physician's prescription to the patient and medical devices require the treating surgeon to decide to use the particular device. The role of the treating physician, therefore, is integral to the treatment of the patients in these claims. A physician's prescription of a drug or use of a device that is or at some point becomes the subject of a mass tort claim, however, does not always amount to malpractice. As a lawyer representing a potential plaintiff, manufacturer, or treating physician, you cannot ignore the actions and the role the treating physician played in the patient's treatment involving the drug or device.
This premium content is locked for Entertainment Law & Finance subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Corporate Enforcement Policy: One Year Later
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Use of Deferred Prosecution Agreements In White Collar Investigations
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
How AI Has Affected PR
When we consider how the use of AI affects legal PR and communications, we have to look at it as an industrywide global phenomenon. A recent online conference provided an overview of the latest AI trends in public relations, and specifically, the impact of AI on communications. Here are some of the key points and takeaways from several of the speakers, who provided current best practices, tips, concerns and case studies.
The DOJ's New Parameters for Evaluating Corporate Compliance Programs
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.